Clinical Studies
IRB Clinical Data on VHT®
Early prototype devices demonstrated 84% closure at 20 weeks.
To validate the data, Vaporox replicated the study in 2019 by recruiting 3 of the top wound care providers in Denver who were treating already chronic wounds. The study achieved nearly identical results at 20 weeks on bigger wounds.
Vaporox will be publishing real world, commercial data with Dr. David Armstrong demonstrating 66% wound closure at 20 weeks (76% at the end of the study). These wounds are significantly larger and have a much lower patient compliance rate than comparable clinical study data.
The VHT-200 underwent IRB testing and has been commercially launched. Both data sets are showing improved treatment efficacy over the earlier studies.
Our 2019 peer-reviewed study can be found in JAPMA.
Clinical Study Overview
Clinical Study Overview